Saturday, March 05, 2005

Suspension of Adderall Sales in Canada - FDA Response

Because of 20 international reports of sudden death in patients (children and adults), Canada has decided to suspend all sales of Adderall XR. Today the FDA announced they "do not feel that any immediate changes are warranted in the FDA labeling or approved use of this drug based upon its preliminary understanding of Health Canada's analyses of adverse event reports and FDA's own knowledge and assessment of the reports received by the agency."

FDA recommends not using stimulant medication in children with known structural heart problems, but families should also be aware that Adderall is often prescribed without any specific guidelines for ruling out heart problems.

Suspension of Adderall RX Sales in Canada

No comments:

Post a Comment